首页> 外文期刊>Journal of vascular and interventional radiology: JVIR >Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis.
【24h】

Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis.

机译:与使用尿激酶和重组组织纤溶酶原激活剂相关的并发症用于导管定向的外周动脉和静脉溶栓。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: Catheter-directed thrombolytic dissolution of peripheral arterial and venous thrombus is in widespread use, yet the frequency and nature of associated complications remain ill defined. In an effort to better characterize the complications associated with urokinase (UK) and recombinant tissue plasminogen activator (rt-PA), the clinical course of patients treated for lower extremity vascular occlusions at a single institution was reviewed. MATERIALS AND METHODS: Over a 9-year period, 653 consecutive patients were treated for lower extremity arterial (527 patients) or venous (126 patients) occlusions with catheter-directed UK (483 patients), rt-PA (144 patients), or both (26 patients). Decisions regarding the choice of thrombolytic agent were made by the clinician. In-hospital complications were subcategorized into hemorrhagic and nonhemorrhagic events and the rate of intracranial hemorrhage was specifically tabulated. RESULTS: There were no significant differences in the demographics or clinical presentation of patients treated with either UK or rt-PA. Bleeding complications occurred less often in the patients treated with UK (insertion site hematoma 21.9% vs. 43.8%, P<.0001, any bleeding necessitating transfusion 12.4% vs. 22.2%, P = .004, and intracranial hemorrhage 0.6% vs. 2.8%, P = .031). Cardiopulmonary complications necessitating transfer to the intensive care unit occurred more frequently in the patients treated with rt-PA (4.9% vs. 1.5%, P = .015). The risk of mortality was not statistically different between the UK and rt-PA treated patients (2.7% vs. 6.2%, P = .221). CONCLUSIONS: Thrombolysis appears safer with UK than with rt-PA, with a lower incidence of hemorrhagic complications. It is possible that this finding is related to differential dosing regimens or intrinsic pharmacologic differences between the agents. The observations of this retrospective analysis require confirmation with a prospective, randomized evaluation.
机译:目的:外周动脉和静脉血栓的导管导向溶栓溶解是广泛的使用,但相关并发症的频率和性质仍然被定义。为了更好地表征与尿激酶(英国)和重组组织纤溶酶原激活剂(RT-PA)相关的并发症,综述了在单一机构对下肢血管闭塞治疗的患者的临床进程。材料和方法:在9年期间,连续653名患者用于下肢动脉(527名患者)或静脉(126名患者)闭塞,与导管 - 指导英国(483名患者),RT-PA(144名患者),或两者(26名患者)。有关临床医生制备溶栓剂的决定。将院内并发症分类为出血性和无震动事件,并且颅内出血率特异性标记。结果:用英国或RT-PA治疗的患者的人口统计数据或临床介绍没有显着差异。用英国治疗的患者较少发生出血并发症(插入部位血肿21.9%,P <.0001,任何出血需要输血12.4%,P = .004,颅内出血0.6%Vs. 2.8%,p = .031)。在RT-PA处理的患者中,需要转移到重症监护病房的心肺并发症更频繁地发生(4.9%vs.1.5%,P = .015)。在英国和RT-PA治疗患者之间的死亡风险没有统计学不同(2.7%对6.2%,P = .221)。结论:溶栓与英国看起来比RT-PA更安全,出血并发症的发病率较低。该发现可能与药剂之间的差分给药方案或内在药理学差异有关。该回顾性分析的观察结果需要确认前瞻性随机评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号